Cargando…
KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease
Monoamine oxidase-B (MAO-B) is a well-established therapeutic target for Parkinson’s disease (PD); however, previous clinical studies on currently available irreversible MAO-B inhibitors have yielded disappointing neuroprotective effects. Here, we tested the therapeutic potential of KDS2010, a recen...
Autores principales: | Nam, Min-Ho, Park, Jong-Hyun, Song, Hyo Jung, Choi, Ji Won, Kim, Siwon, Jang, Bo Ko, Yoon, Hyung Ho, Heo, Jun Young, Lee, Hyowon, An, Heeyoung, Kim, Hyeon Jeong, Park, Sun Jun, Cho, Doo-Wan, Yang, Young-Su, Han, Su-Cheol, Kim, Sangwook, Oh, Soo-Jin, Jeon, Sang Ryong, Park, Ki Duk, Lee, C. Justin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608967/ https://www.ncbi.nlm.nih.gov/pubmed/34611843 http://dx.doi.org/10.1007/s13311-021-01097-4 |
Ejemplares similares
-
Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model
por: Park, Su Eun, et al.
Publicado: (2022) -
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease
por: Park, Jong-Hyun, et al.
Publicado: (2019) -
Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
por: Cho, Hyun-U, et al.
Publicado: (2021) -
Autoinflammatory Keratinization Diseases (AiKDs): Expansion of Disorders to Be Included
por: Akiyama, Masashi
Publicado: (2020) -
Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis
por: Won, Woojin, et al.
Publicado: (2022)